![Michael Houston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Houston
Geen lopende functies
Profiel
Michael Houston worked as Chemistry Director at Cytovax Biotechnologies, Inc. He then worked as Vice President-Chemistry & Formulations at MDRNA, Inc. and later as Vice President-Preclinical Chemistry at Anchor Therapeutics, Inc. He also served as Vice President-Chemistry & Formulations at Adhera Therapeutics, Inc. from 2004 to 2012.
From 2014 to 2017, he was the Chief Scientific Officer at PhaseRx, Inc. Dr. Houston received his undergraduate and doctorate degrees from The University of Waterloo.
Eerdere bekende functies van Michael Houston
Bedrijven | Functie | Einde |
---|---|---|
PHASERX, INC. | Hoofd Techniek/Wetenschap/O&O | 12-10-2017 |
ADHERA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
MDRNA, Inc.
![]() MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Corporate Officer/Principal | - |
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Cytovax Biotechnologies, Inc. | Corporate Officer/Principal | - |
Opleiding van Michael Houston
The University of Waterloo | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ADHERA THERAPEUTICS, INC. | Health Technology |
PHASERX, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
MDRNA, Inc.
![]() MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
Cytovax Biotechnologies, Inc. | Commercial Services |
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |